semaglutide for hfpef Design and Baseline Characteristics of STEP-HFpEF Program Evaluating in Patients With Obesity Phenotype Semaglutide in Patients With Obesity

In clinical trials of semaglutide for weight loss, 44 percent of participants experienced nausea and 31 percent had diarrhea

Nonetheless, this association diminished when confounding factors, such as smoking behavior and educational attainment, were included in the multivariate analysis (Hu et al., 2024)

These pathways collectively promote the proliferation, differentiation, survival, and activation of target cells, including macrophages, microglia, and monocytes [5][10][11]

Better blood pressure and lipid control: Even among people already taking standard therapies, GLP-1s further reduce systolic blood pressure and LDL cholesterol